Structural Insights Into the High Selectivity of the Anti-Diabetic Drug Mitiglinide
Overview
Authors
Affiliations
Mitiglinide is a highly selective fast-acting anti-diabetic drug that induces insulin secretion by inhibiting pancreatic K channels. However, how mitiglinide binds K channels remains unknown. Here, we show the cryo-EM structure of the SUR1 subunit complexed with mitiglinide. The structure reveals that mitiglinide binds inside the common insulin secretagogue-binding site of SUR1, which is surrounded by TM7, TM8, TM16, and TM17. Mitiglinide locks SUR1 in the NBD-separated inward-facing conformation. The detailed structural analysis of the mitiglinide-binding site uncovers the molecular basis of its high selectivity.
AI-Based Discovery and CryoEM Structural Elucidation of a K Channel Pharmacochaperone.
ElSheikh A, Driggers C, Truong H, Yang Z, Allen J, Henriksen N bioRxiv. 2024; .
PMID: 39282384 PMC: 11398524. DOI: 10.1101/2024.09.05.611490.
Membrane transporters in drug development and as determinants of precision medicine.
Galetin A, Brouwer K, Tweedie D, Yoshida K, Sjostedt N, Aleksunes L Nat Rev Drug Discov. 2024; 23(4):255-280.
PMID: 38267543 PMC: 11464068. DOI: 10.1038/s41573-023-00877-1.
The inhibition mechanism of the SUR2A-containing K channel by a regulatory helix.
Ding D, Hou T, Wei M, Wu J, Chen L Nat Commun. 2023; 14(1):3608.
PMID: 37330603 PMC: 10276813. DOI: 10.1038/s41467-023-39379-4.
K channels in focus: Progress toward a structural understanding of ligand regulation.
Martin G, Patton B, Shyng S Curr Opin Struct Biol. 2023; 79:102541.
PMID: 36807078 PMC: 10023423. DOI: 10.1016/j.sbi.2023.102541.